Psych Congress 2026
All poster presentations will take place on Thursday, September 17, from 1:15 PM – 3:30 PM CDT and Friday, September 18, from 1:15 PM – 3:30 PM CDT.
Additional Congress activities include Definium’s medical affairs booth located at #912, and details of the poster presentations are as follows:
|
Title |
|
Session/Location |
|
Invited Oral Presentation |
|
|
|
Latest Discoveries & Emerging Trends in MDD |
|
Thursday, September 17th 9:00 AM - 10:00 AM CDT Great Hall A |
|
Posters |
Poster # |
|
|
Phase 3 Topline Results of DT120 (lysergide) in Generalized Anxiety Disorder |
195 |
Poster Hall |
|
Phase 3 Topline Results of DT120 (lysergide) in Major Depressive Disorder |
115 |
Poster Hall |
|
DT120 (lysergide) Safety Profile from Phase 1 and Phase 2 Clinical Studies |
198 |
Poster Hall |
|
Phase 3 trial design and methodology: treatment with DT120 (lysergide) in Generalized Anxiety Disorder (GAD) & Major Depressive Disorder (MDD) |
196 |
Poster Hall |
|
Suicidal Ideation Frequency Across Generalized Anxiety Disorder, Major Depressive Disorder, and Comorbid Cohorts: The Roles of Symptom Severity, Diagnosis, and Undetected Disorder Burden |
192 |
Poster Hall |
|
DT120 for Major Depressive Disorder: Number Needed to Treat (NNT) and Number Needed to Harm (NNH) |
125 |
Poster Hall |